CAI trades 17.9% above Wall Street's consensus target of $26.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CAI achieves its forward estimates and maintains a stable P/E multiple of 261.6x. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Caris Life Sciences, Inc. (CAI) has a Wall Street consensus price target of $26.00, based on estimates from 7 covering analysts. With the stock currently trading at $31.65, this represents a potential downside of -17.9%. The company has a market capitalization of $8.95B.
Analyst price targets range from a low of $21.00 to a high of $33.00, representing a 46% spread in expectations. The median target of $26.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CAI trades at a trailing P/E of -17.0x and forward P/E of 261.6x. Analysts expect EPS to grow -67.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 EXASExact Sciences Corporation | $20.0B | $104.91 | $92.95 | -11.4% | Buy | 582.8x | 41 |
 ILMNIllumina, Inc. | $38.6B | $255.38 | $210.67 | -17.5% | Buy | 47.7x | 50 |
 NTRANatera, Inc. | $56.0B | $390.79 | $335.07 | -14.3% | Buy | — | 28 |
 GHGuardant Health, Inc. | $23.4B | $176.31 | $199.40 | +13.1% | Buy | — | 31 |
 FDMT4D Molecular Therapeutics, Inc. | $784M | $15.00 | $26.00 | +73.3% | Buy | — | 14 |
 CDNACareDx, Inc | $2.8B | $54.31 | $58.75 | +8.2% | Buy | 45.1x | 13 |
 PACBPacific Biosciences of California, Inc. | $438M | $1.41 | $1.18 | -16.3% | Buy | — | 18 |
 CERTCertara, Inc. | $1.3B | $8.64 | $7.75 | -10.3% | Buy | 25.3x | 16 |
 ACMRACM Research, Inc. | $5.2B | $80.67 | $113.20 | +40.3% | Buy | 36.0x | 10 |
 TMOThermo Fisher Scientific Inc. | $247.2B | $665.30 | $623.36 | -6.3% | Buy | 26.5x | 43 |
Quick answers to the most common questions about buying CAI stock.
CAI's consensus price target is $26, -17.9% below the current price of $31.65. The 7 analysts tracking CAI see downside risk at present valuations.
CAI has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $26 implies -17.9% downside from current levels.
At a forward P/E of 261.5702x, CAI trades at a premium valuation. The consensus price target of $26 (-17.9% downside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $33 for CAI, while the most conservative target is $21. The consensus of $26 represents the median expectation. These targets typically reflect 12-month expectations.
CAI is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CAI stock forecast based on 7 Wall Street analysts shows a consensus price target of $26, with estimates ranging from $21 (bear case) to $33 (bull case). The median consensus rating is "Buy".
CAI trades at a forward P/E ratio of 261.6x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on CAI, with 0 Sell ratings and a price target of $26 (-17.9% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CAI analyst price targets range from $21 to $33, a 46% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $26 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.